Key Highlights

  • AbbVie shares are trading near a 52-week high, up 2.47% to $273.27 in Wednesday's session.
  • The FDA granted two Breakthrough Therapy Designations for Temab-A, in colorectal and lung cancer.
  • A separate Phase 3 trial of epcoritamab combined with standard chemotherapy showed a 51% reduction in disease progression or death risk in frontline lymphoma patients.
  • A brokerage raised its price target to $310 following the designations.

Two Regulatory Wins Reinforce the Oncology Pipeline

AbbVie (NYSE:ABBV), a global biopharmaceutical company, is trading modestly higher in Wednesday's session after the FDA granted two Breakthrough Therapy Designations for telisotuzumab adizutecan, known as Temab-A, an investigational antibody-drug conjugate targeting the c-Met protein. One designation covers Temab-A in combination with bevacizumab for refractory metastatic colorectal cancer, while the second applies to Temab-A as a monotherapy for a specific non-small cell lung cancer population, marking the first such designations for the asset and bringing the company's antibody-drug conjugate portfolio to four Breakthrough Therapy Designations in total.

A Separate Late-Stage Lymphoma Trial Adds to the Momentum

Days earlier, the company and a partner firm reported positive topline results from a Phase 3 trial combining the bispecific antibody epcoritamab with standard frontline chemotherapy in newly diagnosed diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma. The combination reduced the risk of disease progression or death by 51% compared to chemotherapy alone, marking the first Phase 3 study of a bispecific antibody combination to show a statistically significant survival benefit in this frontline setting. The companies plan to engage global regulators on next steps.

A research firm raised its price target on the stock to $310 from $296 following the designations, citing the strength of the broader pipeline update.

Pipeline Strength Offsets a Recent Guidance Trim

The stock is trading near its 52-week high of $274.94, outpacing a softer broader market, as investors weigh today's regulatory news against a modest guidance trim tied to recent acquisition-related dilution. With third-quarter Earnings scheduled for October 30, the company's expanding oncology pipeline, anchored by its existing immunology and oncology franchises, continues to provide an offsetting narrative to near-term cost pressures.